CALCITRIOL INJECTION USP SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

CALCITRIOL

Saadav alates:

STERIMAX INC

ATC kood:

A11CC04

INN (Rahvusvaheline Nimetus):

CALCITRIOL

Annus:

1MCG

Ravimvorm:

SOLUTION

Koostis:

CALCITRIOL 1MCG

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

15G/50G

Retsepti tüüp:

Prescription

Terapeutiline ala:

VITAMIN D

Toote kokkuvõte:

Active ingredient group (AIG) number: 0113628002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2013-01-29

Toote omadused

_ _
_Calcitriol Injection USP Product Monograph _
_Page 1 of 24 _
_ _
PRODUCT MONOGRAPH
PR
CALCITRIOL INJECTION USP
1 mcg/mL
Vitamin D
3
Metabolite
SteriMax Inc.
2770 Portland Drive
Oakville, ON
Canada
L6H 6R4
Date of Revision:
February 24, 2023
Control No : 241232
_ _
_Calcitriol Injection USP Product Monograph _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
..................................................